RecruitMe Clinical Trial

Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce Injection and Intravesical Instillation in Subjects with Urothelial Carcinoma
Study of NanoDoce Injection and as Fluid Inserted in Bladder in Subjects with Bladder Cancer
Sponsor:NanOlogy, LLC
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS3837
U.S. Government ID:NCT03636256
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder by catheter) right after the injection. The purpose of this study is to find the dose which is tolerated the best, gives the least side effects when injected directly into the resected bladder and instilled in the bladder, and to find out which dose may kill cancer cells.

Do You Qualify?
Are you at least 18 years old?YesNo
Do you have metatstatic invasive bladder cancer (MIBC)?YesNo
Are you able to perform everyday activities independently?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162